Published in Breast Cancer Res Treat on January 28, 2014
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol (2015) 0.82
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) (2015) 0.78
Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Res Treat (2017) 0.75
Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging (2015) 0.75
Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. BMJ Open (2017) 0.75
Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clin Transl Oncol (2017) 0.75
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
Development of a comorbidity index using physician claims data. J Clin Epidemiol (2000) 19.31
Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care (2005) 7.73
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer (2007) 3.32
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol (1999) 2.66
ERBB2 inhibition and heart failure. N Engl J Med (2012) 2.23
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21
Trastuzumab-associated cardiotoxicity. Cancer (2002) 2.06
Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail (2011) 1.19
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol (2011) 1.10
Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis (2010) 1.04
Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc (2008) 0.99
Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev (2010) 0.98
Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep (2012) 0.86
Development of a comorbidity index using physician claims data. J Clin Epidemiol (2000) 19.31
Racial differences in the treatment of early-stage lung cancer. N Engl J Med (1999) 9.65
Rising incidence of renal cell cancer in the United States. JAMA (1999) 9.57
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA (2000) 6.37
Prostate cancer screening: what we know and what we need to know. Ann Intern Med (1993) 5.84
Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. JAMA (1999) 3.37
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst (1999) 3.25
Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA (2000) 3.18
Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care (1999) 3.15
Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst (2001) 3.00
Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst (1996) 2.91
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care (1995) 2.55
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet (2005) 2.13
Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia (2001) 2.02
Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Adolesc Psychiatry (1996) 1.98
Undertreatment of glaucoma among black Americans. N Engl J Med (1991) 1.93
Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer. Med Care (2000) 1.90
Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care (1998) 1.88
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet (2001) 1.87
Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol (2001) 1.86
Use of Medicare hospital and physician data to assess breast cancer incidence. Med Care (1999) 1.85
Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. Am J Public Health (1994) 1.84
Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer (1999) 1.84
Cost of care for cancer in a health maintenance organization. Health Care Financ Rev (1997) 1.81
Intravenous drug misuse among prison inmates: implications for spread of HIV. BMJ (1991) 1.80
Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns (1997) 1.75
Determination of lung cancer incidence in the elderly using Medicare claims data. Am J Epidemiol (1993) 1.74
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72
The impact and cost of influenza in the elderly. Arch Intern Med (1993) 1.65
Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Eur J Cancer Care (Engl) (2008) 1.55
Use of preventive services by managed care enrollees: an updated perspective. Health Aff (Millwood) (2000) 1.54
Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst (1996) 1.52
Lactose intolerance: analysis of underlying factors. Eur J Clin Invest (2003) 1.45
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol (1999) 1.41
Measuring the incidence of cancer in elderly Americans using Medicare claims data. Cancer (1994) 1.37
Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study. Med Care (2000) 1.36
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34
Continuing differences in the rates of percutaneous transluminal coronary angioplasty and coronary artery bypass graft surgery between elderly black and white Medicare beneficiaries. Am Heart J (1994) 1.32
The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey. Prev Med (1990) 1.32
BRCA1/2 testing: complex themes in result interpretation. J Clin Oncol (2001) 1.30
Thirty years of Medicare: impact on the covered population. Health Care Financ Rev (1996) 1.29
Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol (1999) 1.27
The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control (1998) 1.25
Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women. Cancer (2001) 1.24
The presidential effect: the public health response to media coverage about Ronald Reagan's colon cancer episode. Public Opin Q (1990) 1.24
Synchronous primary cancers of the endometrium and ovary. Int J Gynecol Cancer (2007) 1.24
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer (2009) 1.24
Assessment of patient preferences among men with prostate cancer. J Urol (1998) 1.19
Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries. Gastrointest Endosc (2001) 1.14
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
Trends and outcomes of outpatient mastectomy in elderly women. J Natl Cancer Inst (1998) 1.11
Spiritual faith and genetic testing decisions among high-risk breast cancer probands. Cancer Epidemiol Biomarkers Prev (2000) 1.11
How sources of health information relate to knowledge and use of cancer screening exams. J Community Health (1992) 1.10
Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk. Health Psychol (2001) 1.07
Spontaneous narrative-discourse performance of parents of autistic individuals. J Speech Hear Res (1991) 1.07
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol (2000) 1.06
BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer (2005) 1.04
"Eat for Health": a supermarket intervention for nutrition and cancer risk reduction. Am J Public Health (1994) 1.04
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer (2011) 1.04
Cell therapy for salivary gland regeneration. J Dent Res (2011) 1.02
The relation between projected breast cancer risk, perceived cancer risk, and mammography use. Results from the National Health Interview Survey. J Gen Intern Med (2005) 0.98
G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Galpha(q) and Galpha(i) signals. Mol Cell Biol (2000) 0.97
Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res (1999) 0.96
Survival and treatment for colorectal cancer Medicare patients in two group/staff health maintenance organizations and the fee-for-service setting. Med Care Res Rev (1999) 0.96
Measuring the incremental cost of clinical cancer research. J Clin Oncol (2001) 0.95
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet (2010) 0.94
Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol (1996) 0.94
Geographic variation in the utilization of esophagoscopy and bronchoscopy in head and neck cancer. Arch Otolaryngol Head Neck Surg (1997) 0.92
Genome-wide scan identifies a susceptibility locus for familial primary cutaneous amyloidosis on chromosome 5p13.1-q11.2. Br J Dermatol (2006) 0.92
Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst (1996) 0.92
The Consensus Development Program. Detecting changes in medical practice following a consensus conference on the treatment of prostate cancer. Int J Technol Assess Health Care (1992) 0.92
Translation of mRNA from calf thymus in the wheat germ system: evidence for a precursor of thymosin alpha1. Proc Natl Acad Sci U S A (1978) 0.92
Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev (2001) 0.91
Human airway smooth muscle expresses 7 isoforms of adenylyl cyclase: a dominant role for isoform V. Am J Physiol Lung Cell Mol Physiol (2001) 0.90
Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res (1998) 0.90
Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol (2013) 0.90
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol (2013) 0.89
Evaluation of perception of insulin therapy among Chinese patients with type 2 diabetes mellitus. Diabetes Metab (2011) 0.89
Comparison of self-reported initial treatment with medical records: results from the prostate cancer outcomes study. Am J Epidemiol (2001) 0.89
Strain-dependent oxygen diffusivity in bovine annulus fibrosus. J Biomech Eng (2009) 0.88
Suggestive linkage of familial primary cutaneous amyloidosis to a locus on chromosome 1q23. Br J Dermatol (2005) 0.87
Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med (2011) 0.87
Effects of exercise training on cardiac apoptosis in obese rats. Nutr Metab Cardiovasc Dis (2012) 0.86
Early views of the martian surface from the Mars Orbiter Camera of Mars Global Surveyor. Science (1998) 0.86
The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. Transplantation (1999) 0.85
The effect of the design of the femoral component on the conformity of the patellofemoral joint in total knee replacement. J Bone Joint Surg Br (2007) 0.85
Radical prostatectomy: does higher volume lead to better quality? J Natl Cancer Inst (1999) 0.84
Medicare Part A utilization and expenditures for psychiatric services: 1995. Health Care Financ Rev (1997) 0.84
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res (1998) 0.84
Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol (2000) 0.83